EX-32 4 blph09301910qexhibit32.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer's knowledge, that:

(1) the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
Date: November 6, 2019
By:
/s/ Fabian Tenenbaum
 
 
Fabian Tenenbaum
Chief Executive Officer
(Principal Executive Officer)

 
 
 
 
 
 
Date: November 6, 2019
By:
/s/ Assaf Korner
 
 
Assaf Korner
Chief Financial Officer
(Principal Financial Officer)